Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Recruiting
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/14/2025
Locations: City of Hope, Duarte, California +6 locations
Conditions: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Recruiting
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Kaiser Permanente - Oakland ( Site 0054), Oakland, California +152 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Recruiting
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Los Angeles Cancer Network, Anaheim, California +5 locations
Conditions: Breast Cancer, Breast Neoplasms
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Recruiting
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/14/2025
Locations: Ep0162 50506, Phoenix, Arizona +172 locations
Conditions: Stereotypical Prolonged Seizures
Nipocalimab in Moderate to Severe Sjogren's Disease
Recruiting
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Providence Medical Foundation, Fullerton, California +121 locations
Conditions: Sjogrens Syndrome
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Recruiting
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/14/2025
Locations: Research Site, Tampa, Florida +26 locations
Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry
Recruiting
The objective of this post market, clinical registry is to evaluate the performance of the products of the TVT family of products or vaginal vault or uterine prolapse repair (with laparotomic or laparoscopic approach including robotic assisted) using either Gynemesh PS Mesh or Artisyn Mesh in women undergoing surgery for SUI and POP.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
08/14/2025
Locations: Yale University, New Haven, Connecticut +10 locations
Conditions: Stress Urinary Incontinence, Pelvic Organ Prolapse
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Recruiting
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/14/2025
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Heart Failure, Polygenic Score
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Recruiting
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
08/14/2025
Locations: Science 37, Inc., Morrisville, North Carolina
Conditions: Von Willebrand Disease (VWD)
GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study
Recruiting
The objective of this retrospective and prospective, single-arm, observational, multicenter, post-market study is to evaluate outcomes in women who underwent surgery for vaginal or uterine prolapse with a GYNEMESH PS Mesh.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
08/14/2025
Locations: Institute for Female Pelvic Medicine, North Wales, Pennsylvania +2 locations
Conditions: Pelvic Organ Prolapse
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Recruiting
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Site Number - 1008, Hialeah, Florida +5 locations
Conditions: Graves' Disease
SELUTION4BTK Trial
Recruiting
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: St. Bernards Medical Center, Jonesboro, Arkansas +40 locations
Conditions: Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities